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Abstract: Historically, the name of natural killer (NK) cells came from their natural ability to 
kill tumor cells in vitro. From the 1970s to date, accumulating data highlighted the importance 
of NK cells in host immune response against cancer and in therapy-induced antitumor response. 
The recognition and the lysis of tumor cells by NK cells are regulated by a complex balance of 
inhibitory and activating signals. This review summarizes NK cell mechanisms to kill cancer 
cells, their role in host immune responses against tumor growth or metastasis, and their impli-
cations in antitumor immunotherapies via cytokines, antibodies, or in combination with other 
therapies. The regulatory role of NK cells in autoimmunity is also discussed.
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Introduction to natural killer cells in antitumor 
immune response
Natural killer (NK) cells were discovered in humans and mice in 1975 due to specific 
functional criteria corresponding to their ability to lyse certain tumor cells in the 
absence of prior stimulation.1 They possess a morphology of large granular lymphocytes 
(Figure 1A) and their receptor genes involved in the recognition of pathogens remain 
in germinal configuration unlike T and B cells.2 Thus, they differ from the T and B 
lymphocytes by the permanent presence of a significant fraction of educated and primed 
cells.3 The formulation of the hypothesis of “missing self” by Klas Kärre, based on the 
fact that NK cells are able to detect and lyse cells with a deficient expression of major 
histocompatibility complex class I (MHC-I) molecules, allowed a better understanding 
of the function and the role of NK cells in the immune response.4 In the 1990s, several 
studies highlighted the presence of inhibiting and activating receptors expressed by NK 
cells5 that led to the identification of a new recognition model called “induced-self.”6 
This new model complements the hypothesis of “missing-self” by explaining why 
NK cells kill tumor cells expressing MHC-I molecules or save autologous cells 
with absent MHC-I expression (Figure 2). Indeed, NK cell triggering is the result 
of a complex balance between inhibitory and activating signals and require not only 
a deficient MHC-I expression on target cells but also the expression of inducible 
ligands of activating NK cell receptors.7 Consequently, these cells have the ability to 
recognize and destroy a wide range of abnormal cells (including tumor cells, virus-
infected cells, cells bound by an antibody, allogeneic cells), as well as stressed cells, 
without damaging the healthy and normal “self” cells.8 Therefore, NK cells have 
several important effector functions such as the initiation and amplification of the 
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inflammatory response, the production of chemokines and 
cytokines, and the lysis of sensitive target cells.9,10
NK cells represent 5% to 20% of peripheral blood 
mononuclear cells, usually defined as CD16+ CD56+ 
CD3- cells and are also found in many tissues such as 
liver, peritoneal cavity, placenta, or the uterine mucosa.11–14 
Human NK cells can be divided into two subpopulations 
according to the density of CD16 and CD56 expression 
on their surface (Figure 3). The majority of NK cells in 
blood (90%–95%) or at inflammation sites have a moder-
ate expression of CD56 (CD56dim) and a strong expression 
of CD16 (Figure 3). These cells possess a high cytotoxic 
potential.15 The CD56bright subpopulation predominates in 
lymph nodes, expresses no or low levels of CD16, displays 
little cytotoxicity, and mainly produces cytokines upon 
activation (Figure 3).16 CD56 is not expressed on mouse NK 
cells, but recently Hayakawa and Smyth17 categorized these 
cells depending on their CD27 expression. Mouse CD27bright 
NK cells share several characteristics with human CD56bright 
NK cells. Accordingly, they predominate in lymph nodes and 
produce large amounts of cytokines. Recently, the discovery 
of a new NK marker, NKp46, allowed to define human and 
mice NK cells because, in contrast to others markers (CD16 
and CD56 for humans or DX5 or NK1.1 for mice), NKp46 
is exclusively expressed by all NK cells in both species.18 
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Figure 1 Electron micrographics of natural killer (A) and NK-92 (B) cells showing 
large lymphocyte-containing granules (arrows).
Note: Scale bar, 2 µm. 
Abbreviation: N, nucleus.
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Figure  2  Recognition  mechanisms  of  target  cells  by  NK  cells:  “missing  and 
induced self” theory. NK cell response is not initiated if neither ligands for NK-
activating  receptors  nor  MHC-I  are  expressed  on  target  cells  (A).  If  inhibitory 
receptors interact with MHC-I molecules without ligands for activating receptors 
no cytotoxicity is observed (B), whereas engagement of these receptors in absence 
of MHC-I molecule induced a strong NK cell response (C). In most cases, NK cell 
response depends on a balance between inhibitory and activating receptor signaling 
(D). Normal cells are protected against NK cell cytotoxicity because they usually 
express MHC-I molecules and no or low level of activating receptor ligands.
Notes: In contrast, cell transformation could induce a down-modulation of MHC-I 
molecules and/or an overexpression of ligands for activating receptors resulting in 
NK cell recognition and tumor cell lysis.
Abbreviations: MHC-I: major histocompatibility complex class I; NK, natural killer.
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Figure 3 Human natural killer cell subsets based on CD56 and CD16 expressions: 
Around 90% of natural killer cells isolated from the blood display dim level of CD56 
and high density of CD16 (CD56dimCD16bright).
Notes: These cells are more cytotoxic via perforin and granzyme secretion15 than 
natural killer cells showing bright expression of CD56 and no or low expression of 
CD16 (CD56brightCD16-/low). These latter cells produce more cytokines.16
Abbreviations:  GM-CSF,  granulocyte–macrophage  colony-stimulating  factor; 
IFN-γ, interferon γ; IL-10, interleukin 10; TNF-α, tumor necrosis factor α.
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Several NK cell lines have been established from lymphoma 
or peripheral blood mononuclear cells such as NK-9219 
(Figure 1B) or NKG,20 respectively.
From their discovery, NK cells were described as white 
blood cells able to lyse tumor cells such as K562, a tumor 
cell line generated from a patient with chronic leukemia.21 
Shortly thereafter, NK cells were shown to eliminate circulat-
ing tumor cells in mice,22 but also to kill spontaneously cells 
deficient for MHC-I.4 The generation of mice genetically 
deficient for NK cells or depleted of these cells by antibodies, 
highlighted that NK cells have a role in immunosurveillance 
of cancer and the ability to prevent the tumor growth.23–25 
Indeed, the transplantation of lymphoma cells in mice con-
duct to a more aggressive tumor growth in NK cell deficient 
mice compared to wild type mice.26
Review of the activation and 
mechanism of action of NK cells
Unlike T and B lymphocytes, NK cells will not rearrange 
their genes encoding for receptor antigen recognition, 
but they have the ability to recognize target cells directly 
through inhibitory or activating receptors expressed on the 
cell   surface. The balance between stimulatory and inhibitory 
signals will determine the activation status of NK cells since 
lysis of the target cell will only happen when the activating 
signals outweigh the inhibitory signals. The first checkpoint 
is the expression of MHC-I molecules.4,27 In fact, downregu-
lation of MHC-I is observed during tumor transformation28 
or viral infection29 and prevents the binding of inhibitory 
receptors of NK cells to the target cell. Simultaneously, 
ligands for activating receptor of  NK cells must be expressed 
on the target cell to trigger NK cell cytotoxicity. These ligands 
are absent or expressed in low amounts on normal cells, 
although they are highly expressed on potentially harmful 
cells as a consequence of cellular stress, viral infection, or 
tumor transformation.
Different mechanisms are known to be involved in the 
destruction of tumor cells by NK cells:
•  Perforin/granzyme-mediated cytotoxicity: The release 
of cytotoxic granules composed of perforin and gran-
zymes30 is the fastest and also the most powerful way to 
lyse tumor cells. By creating a synapse with the target 
cell, NK cells will drop, at this junction, perforin and 
granzyme molecules inducing the lysis of the target cell.31 
Mice deficient for perforin are less efficient (about 10 to 
100 times) to suppress syngeneic MHC-I deficient tumor 
cells, suggesting that this molecule is required for NK 
cell cytotoxicity.32 Moreover, many studies have shown 
that perforin is important for the immunosurveillance of 
several spontaneous malignancies33 whereas the role of 
granzymes is less characterized.34
•  Death receptor mediated apoptosis: The death of the 
target cell, induced by apoptosis via tumor necrosis fac-
tor (TNF) family ligands, Fas ligand (CD178), TNF, and 
TRAIL (tumor-necrosis factor-related apoptosis-inducing 
ligand),35 is an alternative to the release of granules. 
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Figure 4 Overview of NK cell responses against tumor cell.
Abbreviations: NK, natural killer; DC, dendritic cell; IFN-γ, interferon γ; IL, interleukin; KIR, killer-cell immunoglobulin-like receptor; mAb, monoclonal antibody; NCR, 
natural cytotoxicity receptor; TNF-α, tumor necrosis factor α.
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This second mechanism, which is slower (several hours) 
and often less efficient than the previous one, requires 
the presence of the TNF family ligand expression on 
the surface of NK cells. These ligands will bind to a 
receptor Fas on the surface of the target cell. The effec-
tiveness of this pathway is controlled by various factors 
such as expression of the receptor for FasL or TRAIL by 
the cancer cells or intracellular mechanisms protecting 
against apoptosis. For example, a murine subset of NK 
cells in liver expressing TRAIL has been shown to kill 
cancer cells and clear tumors from the liver.36
•  Interferon-γ effector functions: After activation, NK cells 
secrete various cytokines such as interferon γ (IFN-γ), 
TNF-α, granulocyte–macrophage colony-stimulating 
factor (GM-CSF), interleukin (IL)-10, or IL-13 and their 
antitumor activities can be mediated by IFN-γ.37 Indeed, 
IFN-γ produced by NK cells contributes to eliminate 
tumor metastases and sarcoma induced by methylcholan-
threne in a murine model.38 This cytokine inhibits pro-
liferation of tumor cells in vitro and indirectly the tumor 
growth in vivo by inducing the antiangiogenic factors, 
IP-10.39 IFN-γ has been also described to enhance NK 
cell cytotoxicity by overexpressing adhesion molecules 
or by increasing the sensitivity of tumor cells to cyto-
toxicity mediated by granule release or death receptor 
engagement.40 TRAIL expression on murine liver NK 
cells is dependent on IFN-γ expression and contributes 
to the natural antimetastatic role of these NK cells.36 
IFN-γ induced TRAIL expression is also implicated in 
the IL-12 mediated anti-metastatic effect.24
Additionally, IFN-γ plays a role in the stimulation of 
dendritic cells (DC). In combination with CD40 engagement, 
IFN-γ induces IL-12 production by DCs.41 In this way, NK 
cells contribute indirectly to tumor control by helping the 
initiation and maintenance of an efficient T cell-mediated 
antitumor response via a crosstalk with DC.42,43
Overview on the NK cells receptor 
types, history, and discovery
NK cell inhibitory receptors
As previously mentioned, it was originally proposed by 
Kärre et al4 that NK cells discriminate target cells from 
normal cells by the level of MHC-I expression on the cell 
surface. NK cells preferentially lyse cells expressing few or 
no MHC-I.44 The sensitivity of cells with low MHC-I expres-
sion to NK cell lysis may be prevented by the re-expression 
of these molecules.45,46 Three families of inhibitory receptors 
recognizing MHC-I molecules were described (Table 1): 
KIR (killer cell immunoglobulin-like receptor, humans),47,48 
Ly49 (mice),49,50 and CD94/NKG2A (human and mice)51–53 
receptor family.
Immunoreceptor tyrosine-based inhibitory motif (ITIM), 
present in all cytoplasmic domains of NK cell inhibitory 
receptors, is able to recruit intracellular tyrosine phosphatases 
SHP-1 and SHP-2, which inhibit cytotoxicity and cytokine 
production.54
KIR receptors are encoded by about twelve polymor-
phic genes and are expressed on NK cells and memory 
T   lymphocytes. The binding to one type of KIR receptor 
is sufficient to prevent activation of NK cells, whereas it 
usually takes several different activating signals to induce 
degranulation and death of the target cell. The CD94/NKG2A 
receptor, conserved in rodents and primates, is expressed 
on most NK cells and a subset of CD8+ memory T cells.55 
CD94 has no cytoplasmic signalization domain while the 
receptor NKG2A contains two ITIM.56 KIR, but also murine 
Ly49 receptors, bind directly to MHC-I molecules, whereas 
the CD94/NKG2A receptor binds to a peptide derived from 
Table1 Main receptors on NK cells involved in anti-tumor immune response
Function Receptors Ligands Species Ref
Inhibition KIR 
(long cytoplasmic tail)
HLA-A,B,C allotypes H 42,43
Ly49A/C MHC class I M 44,45
CD94-NKG2A MHC-E H, M 48,50
Activation CD16 IgG H, M
HPV H 61
NKG2D MICA/B-RAET H
RAET-H60 M
NKp30 B7-H6, Heparan sulfate H 75–78
NKp44 Heparan sulfate H 76
NKp46 Heparan sulfate, unknown tumor ligands H, M 75,76,121
Abbreviations: HLA, human leucocyte antigen; H, Human; Ig, immunoglobulin; M, mouse; MHC, major histocompatibility complex; MICA/B, major histocompatibility 
complex class I-related; RAET, retinoic acid early transcript.
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the signal sequence of MHC-I.50,54 All inhibitory receptors 
are found by overlapping NK cell subpopulations since 
each cell expresses only a few types of inhibitory receptors. 
Consequently, NK cells have many complex combinations 
of MHC-I repertoire randomly distributed on the cells. The 
only rule that seems to be established is that all NK cells have 
at least one inhibitory receptor specific for MHC-I molecule 
to avoid autoreactivity.
NK cell-activating receptors
In addition to inhibitory receptors, NK cells express a wide 
range of activating receptors. Their biological role is not yet 
fully known because all their ligands have not been   identified. 
The main activating receptors involved in tumor lysis are 
CD16, NKG2D receptor, and the natural cytotoxicity recep-
tors (NCR)57–60 (Table 1).
The activating receptors have no ITIM in their cyto-
plasmic domains. Instead, they have charged residues in 
their transmembrane domains, which are necessary for the 
association with adapter proteins. These proteins have short 
extracellular domains and, therefore, do not participate in 
ligand binding. The intracellular domains of these adapter 
proteins have docking sites for signaling molecules that play 
a role downstream of the stimulation. Most of the adapter 
proteins (FcεRγI, CD3ζ, DAP12, and DAP10) contain 
immunoreceptor tyrosine-based activation motif in their 
cytoplasmic domains, which enable them to associate with 
ZAP70 and/or proteins of syk kinases family.61,62
CD16 is a low-affinity receptor for the Fc portion of 
immunoglobulin (FcγRIII). This receptor with a transmem-
brane domain (FcγRIIIa) is found on the surface of NK 
cells but also on some DC, T lymphocytes, monocytes, and 
macrophages, and a glycosylphosphatidylinositol-linked 
receptor (FcγRIIIb) is expressed on neutrophils.63 When 
IgG molecules recognize specific antigens on a tumor cell, 
NK cells, via CD16, are able to bind tumor cell coated 
with antibodies and induce tumor cell death. This reaction 
called antibody-dependent cell-mediated cytotoxicity is a 
dominant component of antibody based immunotherapy 
against tumors.64 Recently, CD16 has been implicated in the 
recognition of human papillomavirus by NK cells in uterine 
preneoplastic lesions.65
NKG2D, unlike the other NKG2 receptors, does not 
have an ITIM sequence and is not associated with CD94.66 
It is expressed on most NK cells but also on γδ and CD8+ 
T cells. It is associated with the adapter molecule DAP10 in 
humans, and DAP10 and DAP12 in mice.67,68 Binding of 
NKG2D ligands, such as MICA or MICB, leads to an increase 
in proliferation, cytotoxicity, and production of cytokines 
and chemokines (IFN-γ, GM-CSF, TNF-α).69 Expression 
of NKG2D ligands is observed on many tumor cell lines 
and tumor tissues.70,71
More specifically expressed on NK cells, the principal 
NCR are NKp46, NKp44, and NKp30.59,72,73 Molecular 
cloning of NCR confirmed that they were structurally 
distinct although they belong to the same immunoglobulin 
superfamily.74 NKp46 (human and mice) and NKp30 (human) 
are expressed on both resting and activated NK cells, while 
the NKp44 receptor is only present on IL-2-activated human 
NK cells and a minor subset of γδ T cells.72 The density of 
NCR on the cell surface varies with individuals and there 
is a direct correlation between NCR expression on human 
NK cells and their capacity to kill tumor cells.75 NKp46, the 
first identified NCR, is a 46 kDa glycoprotein with a trans-
membrane domain that interacts with the adapter molecule 
CD3ζ.59,76 The activation of NKp46 leads to mobilization of 
calcium in the development of cytolytic activity and cytokine 
production.59 Monoclonal antibodies against NKp46 block the 
lysis of a wide range of tumor cells showing that this receptor 
plays a major role in NK cell cytotoxicity.77 This function of 
NKp46 is negatively regulated by the interaction between 
inhibitory receptors and MHC-I. NKp44 is a 44 kDa glyco-
protein whose expression is inducible by IL-2, suggesting 
that it could contribute to the increased efficiency of activated 
NK cells to lyse tumor cells.72 NKp44 acts in association 
with the immunoreceptor tyrosine-based activation motif 
on the adapter molecule DAP12. The blocking of NKp44 
by monoclonal antibodies induces a partial inhibition of the 
cytolytic activity against some tumor cells and this inhibition 
is strongly enhanced by the addition of antibodies blocking 
NKp46.78 NKp30 is a glycoprotein of 30 kDa that associates 
with the adapter molecules CD3ζ and FcεRγI.73 Its expres-
sion at the cell surface is correlated with NKp46. In addition, 
NKp30 cooperates with NKp46 and NKp44 to induce NK cell 
cytotoxicity against a variety of target cells.73 NKp46, NKp44, 
and NKp30 bind to heparan sulfates on the surface of tumor 
cells.79,80 In addition, NKp30 is involved in the lysis of tumor 
cells by binding to factor BAT3 (HLA-B associated transcript 
(3) or to B7-H6 present on their surface.81,82
Role of NK cells in immune 
response against tumor growth  
and metastasis
In vivo and in vitro studies have shown that NK cells can 
eliminate tumor cells.83 In mice, tumor rejection is dependent 
upon the presence or absence of NK cell receptor ligands on 
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the tumor. Especially the lack of MHC-I expression, over-
expression of NKG2D ligands (H60, Rae1β, Rae1δ, Rae1γ, 
Mult-1), or costimulatory signals makes the tumor more sus-
ceptible to lysis by NK cells.84 Moreover, engagement of NCR 
complements NKG2D pathway in the killing of tumor cells by 
NK cells.85 Little is known about the mechanism of NK cell 
migration in tumor, but selectins seem to play a role in this 
recruitment.86 However, Smyth et al25,87 showed that mice defi-
cient in NK cells are more susceptible to methylcholanthrene-
induced sarcomas, demonstrating that NK cells play a role 
in tumor immunosurveillance. NK cells also protect against 
the growth of B cell lymphomas in mice lacking perforin and 
β2 microglobulin.88 Moreover, NK cells participate to immune 
response against metastasis; in an immunotherapy protocol 
using synthetic oligodeoxynucleotides containing CpG motifs, 
NK cells prevent pulmonary metastasis and peritoneal dis-
semination.89 In a mouse model, NK cells inhibit pulmonary 
metastasis formation after IFN-γ treatment.90
Also, in humans, there is evidence that NK cells play a 
role in the tumor immunosurveillance. An 11-year follow-up 
survey has shown that a low NK cell activity is associated 
with an increased cancer risk.91 This was confirmed in several 
human malignancies. For example, a decrease of NK cell 
activity is observed in patients with hereditary colorectal 
adenocarcinoma92,93 and melanoma patients with metastatic 
disease have an impaired perforin-dependent NK cell cyto-
toxic mechanism.94 Tumor growth can disturb the functional 
maturation of NK cells by interrupting the IL-15 signaling 
pathway,95 but further studies are necessary to better under-
stand the immunologic basis of NK cell defects in tumor.
As already mentioned, NK cells collaborate with antigen-
presenting cells to amplify the immune response.96 This 
collaboration can help to induce a T cell-mediated antitumor 
immunity.97 After the implantation of MHC-I low tumor cells 
in mice, the release of IFN-γ by NK cells stimulate the matura-
tion of DC to a IL-12-producing DC1 phenotype that promote 
a strong and protective antitumor CD8+ T cell response.42,98
Implications for tumor 
management
The observation that IL-2 increased in vitro the cytotoxic 
activity of NK cells against tumor cells99 has been con-
ducted to perform clinical trials with adoptive transfer 
of high doses of this cytokine in patients with metastatic 
melanoma or renal cell carcinoma.100,101 Due to systemic 
toxicity of IL-2 and to the fact that IL-2 preferentially drives 
expansion of regulatory T cells, which can inhibit antitumor 
immunity, other cytokines, such as IL-15, were tested in 
nonhuman primates. IL-15 shares similar properties with 
IL-2 and Berger et al102 showed that intermittent administra-
tion of IL-15 should be considered in clinical studies. Also 
other cytokines, such as IL-12 and IL-18, synergistically 
enhance NK cytotoxicity against tumor targets and IFN-γ 
production by NK cells.103,104
Tumor-targeted monoclonal antibodies can induce NK 
cell antibody-dependent cell-mediated cytotoxicity and 
the rapid degranulation of NK cells results in tumor cell 
destruction.105 The clinical efficacy of monoclonal antibodies 
directed against CD20 (rituximab), Her2/neu (trastuzumab), 
epidermal growth factor receptor (cetuximab), or disialo-
ganglioside (GD2) is, at least partially, due to NK antibody-
dependent cell-mediated cytotoxicity.106–109 Moreover, in a 
Phase I trial, coadministration of IL-12 with trastuzumab 
enhances the antitumor response induced by the antibody.110
Besides the development of protocols to stimulate NK 
cell activity, inhibitory receptors on NK cells could be the 
target for antitumor therapy. Blocking Ly49 inhibitory recep-
tors enhanced antitumor activity in vitro and in vivo111 and 
in human, antibodies blocking KIR are currently tested in a 
Phase II clinical trial.112 NK allogeneic recognition via their 
KIR repertoire has a major role in reducing the risk of relapse 
by inducing a graft versus leukemia effect after allogeneic 
hematopoietic stem cell transplantation.113
NK cells seem important in tumor vaccination with DC, 
since clinical responses are correlated with superior levels of 
activated NK cells in responders.114 In a Phase I clinical trial 
with melanoma patients, DC derived-exosomes enhanced 
NKG2D-dependent function of NK cells in half of the 
patients.115 Indirectly, immunotherapy protocols targeting 
an oncogenic viral protein116 or the recruitment of antigen-
presenting cells117 boost NK cell response. Even some chemo-
therapeutic agents could inhibit secretion of inhibitory soluble 
NKG2D ligands.118 A NK cell treatment combined with radia-
tion therapy has been proposed, since radiation increases NK-
activating ligand (eg, NKG2DL) expression via DNA damage 
response.119 Figure 4 summarizes the different mechanisms 
implicated into NK cell response against tumor cells.
Role of NK cells in autoimmunity
NK cells are viewed as effector cells whose rapid killing of 
transformed or infected cells provides a first-line of defense 
prior to the initiation of an adaptive immune response against 
tumor or infection. However, studies on NK cells suggest a 
broad role in immunity including the potential to function as 
regulatory cells. While NK cells can assist in DC maturation and 
T cell polarization, increasing evidence indicates that NK cells 
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can also prevent and limit adaptive autoimmune responses.120 
Autoimmune diseases are a multistep process caused by inap-
propriate activation of cells of the adaptive immune system 
(T and B cells) which results in cell-specific, organ-specific, 
or systemic tissue damage.121 Autoimmunity has been linked 
to cancer, for example, patients with scleroderma have an 
increased risk to develop a tumor.122 Moreover autoimmunity 
is associated with immunotherapy of cancer.123
Several studies suggested that NK cells play a role at 
the different stages of the autoimmune response.124 NK cells 
can either augment or ameliorate autoimmune diseases.125,126 
A reduction of circulating NK cells has been shown in diverse 
autoimmune diseases, which contributed to an impaired NK 
activity.127,128 The modulation in the number of circulating NK 
cells seems to be a primary event instead of an active inflam-
mation/drug administration consequence during autoimmune 
processes. However, some biotherapies are linked with 
changes of circulating NK cells compartment. Daclizumab 
(anti-IL-2Rα) treatment in multiple sclerosis129 or in uveitis130 
pathogenesis is associated with an increase in the number of 
CD56bright NK cells. This augmentation of CD56bright NK cells 
is correlated with the suppression of the disease activity.129 NK 
cells can also promote autoimmune diseases, ie, autoimmune 
diabetes is prevented in nonobese-diabetic mice by blocking 
the activating NK cell receptor NKG2D.131 In humans, the 
predisposition to rheumatoid arthritis,132 psoriatic arthritis,133 
scleroderma,134 and psoriasis vulgaris135 is linked to the expres-
sion of certain KIR and HLA alleles, but the precise role of 
NK cells in these diseases is still under investigation.
Conclusion
NK cells could be very efficient killers of tumor cells and 
could help to induce an optimal adaptive immune response 
against cancer. A better knowledge in the basic biology of 
NK cells is a key to develop strategies to manipulate NK 
cells for therapeutic purposes.
Acknowledgments
IL and VMR are supported by a Télévie grant from the 
Belgian National Fund for Scientific Research (FNRS) and 
NJ is a research associate of the FNRS.
References
1.  Kiessling R, Klein E, Wigzell H. “Natural” killer cells in the mouse. I. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells. 
Specificity and distribution according to genotype. Eur J Immunol. 
1975;5(2):112–117.
2.  Biron CA, van den Elsen P, Tutt MM, Medveczky P, Kumar V , Terhorst C. 
Murine natural killer cells stimulated in vivo do not express the T cell 
receptor alpha, beta, gamma, T3 delta, or T3 epsilon genes. J Immunol. 
1987;139(5):1704–1710.
  3.  Di Santo JP. Natural killer cell developmental pathways: a question of 
balance. Annu Rev Immunol. 2006;24:257–286.
  4.  Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of 
H-2-deficient lymphoma variants suggests alternative immune defence 
strategy. Nature. 1986;319(6055):675–678.
  5.  Lanier LL. Natural killer cells: from no receptors to too many. Immunity. 
1997;6(4):371–378.
  6.  Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer 
cell receptor repertoire. Annu Rev Immunol. 2001;19:291–330.
  7.  Lanier LL. Missing self, NK cells, and the white album. J Immunol. 
2005;174(11):6565.
  8.  Caligiuri MA. Human natural killer cells. Blood. 2008;112(3): 
461–469.
  9.  Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of 
natural killer cells. Nat Immunol. 2008;9(5):503–510.
  10.  Wu J, Lanier LL. Natural killer cells and cancer. Adv Cancer Res. 
2003;90:127–156.
  11.  King A, Burrows T, Loke YW. Human uterine natural killer cells. Nat 
Immun. 1996;15(1):41–52.
  12.  Luo D, Vermijlen D, Vanderkerken K, et al. Involvement of LFA-1 in 
hepatic NK cell (pit cell)-mediated cytolysis and apoptosis of colon 
carcinoma cells. J Hepatol. 1999;31(1):110–116.
  13.  Robertson MJ, Ritz J. Biology and clinical relevance of human natural 
killer cells. Blood. 1990;76(12):2421–2438.
  14.  Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989; 
47:187–376.
  15.  Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of 
human FcRIII-positive and negative natural killer cells. J Immunol. 
1989;143(10):3183–3191.
  16.  Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: 
a unique innate immunoregulatory role for the CD56(bright) subset. 
Blood. 2001;97(10):3146–3151.
  17.  Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two 
subsets with distinct responsiveness and migratory capacity. J Immunol. 
2006;176(3):1517–1524.
  18.  Walzer T, Blery M, Chaix J, et al. Identification, activation, and selective 
in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci   
U S A. 2007;104(9):3384–3389.
  19.  Gong JH, Maki G, Klingemann HG. Characterization of a human 
cell line (NK-92) with phenotypical and functional characteristics of 
activated natural killer cells. Leukemia. 1994;8(4):652–658.
  20.  Cheng M, Ma J, Chen Y, et al. Establishment, characterization and 
successful adaptive therapy against human tumors of NKG Cell,   
a new human NK cell line. Cell Transplant. June 7, 2011. [Epub ahead 
of print.]
  21.  Ortaldo JR, Oldham RK, Cannon GC, Herberman RB. Specificity of 
natural cytotoxic reactivity of normal human lymphocytes against a 
myeloid leukemia cell line. J Natl Cancer Inst. 1977;59(1):77–82.
  22.  Riccardi C, Santoni A, Barlozzari T, Puccetti P, Herberman RB. 
In vivo natural reactivity of mice against tumor cells. Int J Cancer. 
1980;25(4):475–486.
  23.  Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo 
natural killer cell activities revealed by natural killer cell-deficient mice. 
Proc Natl Acad Sci U S A. 2000;97(6):2731–2736.
  24.  Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-
dependent natural killer cell protection from tumor metastasis. J Exp 
Med. 2001;193(6):661–670.
  25.  Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate 
in host protection from methylcholanthrene-induced fibrosarcoma. Int 
Immunol. 2001;13(4):459–463.
  26.  Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, 
  Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the 
absence of the NK-activating receptor NKp46/NCR1. J Immunol. 2009; 
182(4):2221–2230.
  27.  Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat 
Rev Microbiol. 2005;3(1):59–69.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
79
NK cells and tumor growthBiologics: Targets and Therapy 2012:6
  28.  Garrido F, Algarra I. MHC antigens and tumor escape from immune 
surveillance. Adv Cancer Res. 2001;83:117–158.
  29.  Hewitt EW. The MHC class I antigen presentation pathway: strategies 
for viral immune evasion. Immunology. 2003;110(2):163–169.
  30.  Clement MV , Haddad P, Soulie A, et al. Involvement of granzyme B 
and perforin gene expression in the lytic potential of human natural 
killer cells. Res Immunol. 1990;141(6):477–489.
  31.  Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, 
coactivation, and costimulation of resting human natural killer cells. 
Immunol Rev. 2006;214:73–91.
  32.  Kagi D, Ledermann B, Burki K, et al. Cytotoxicity mediated by T cells 
and natural killer cells is greatly impaired in perforin-deficient mice. 
Nature. 1994;369(6475):31–37.
  33.  Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. 
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous 
lymphoma. J Exp Med. 2000;192(5):755–760.
  34.  Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are impor-
tant for regulatory T cell-mediated suppression of tumor clearance. 
Immunity. 2007;27(4):635–646.
  35.  Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. 
Natural killer (NK) cell-mediated cytotoxicity: differential use of 
TRAIL and Fas ligand by immature and mature primary human NK 
cells. J Exp Med. 1998;188(12):2375–2380.
  36.  Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necro-
sis factor-related apoptosis-inducing ligand in surveillance of tumor 
metastasis by liver natural killer cells. Nat Med. 2001;7(1):94–100.
  37.  Trinchieri G. Natural killer cells wear different hats: effector cells of 
innate resistance and regulatory cells of adaptive immunity and of 
hematopoiesis. Semin Immunol. 1995;7(2):83–88.
  38.  Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma 
activities independently control tumor initiation, growth, and metastasis. 
Blood. 2001;97(1):192–197.
  39.  Angiolillo AL, Sgadari C, Taub DD, et al. Human interferon-inducible 
protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med. 
1995;182(1):155–162.
  40.  Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. 
Natural killer cells in antiviral defense: function and regulation by 
innate cytokines. Annu Rev Immunol. 1999;17:189–220.
  41.  Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 
production by human dendritic cells requires two signals. Int Immunol. 
1998;10(11):1593–1598.
  42.  Adam C, King S, Allgeier T, et al. DC-NK cell cross talk as a novel 
CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 
2005;106(1):338–344.
  43.  Jacobs N, Boniver J, Hubert P, Delvenne P. Dendritic cells: more than 
just adaptive immunity inducers? Curr Immunol Rev. 2007;3:17–22.
  44.  Ljunggren HG, Kärre K. Host resistance directed selectively against 
H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp 
Med. 1985;162(6):1745–1759.
  45.  Franksson L, George E, Powis S, Butcher G, Howard J, Kärre K. Tum-
origenicity conferred to lymphoma mutant by major histocompatibility 
complex-encoded transporter gene. J Exp Med. 1993;177(1): 
201–205.
  46.  Ljunggren HG, Sturmhofel K, Wolpert E, Hammerling GJ, Kärre K. 
Transfection of beta 2-microglobulin restores IFN-mediated protection 
from natural killer cell lysis in YAC-1 lymphoma variants. J Immunol. 
1990;145(1):380–386.
  47.  Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. 
Killer cell inhibitory receptors specific for HLA-C and HLA-B 
identified by direct binding and by functional transfer. Immunity. 
1995;3(6):801–809.
  48.  Jamil KM, Khakoo SI. KIR/HLA interactions and pathogen immunity. 
J Biomed Biotechnol. 2011;2011:298348.
  49.  Yokoyama WM, Jacobs LB, Kanagawa O, Shevach EM, Cohen DI.   
A murine T lymphocyte antigen belongs to a supergene family 
of type II integral membrane proteins. J Immunol. 1989;143(4): 
1379–1386.
  50.  Orr MT, Lanier LL. Inhibitory Ly49 receptors on mouse natural killer 
cells. Curr Top Microbiol Immunol. 2011;350:67–87.
  51.  Carretero M, Cantoni C, Bellon T, et al. The CD94 and NKG2-A C-type 
lectins covalently assemble to form a natural killer cell inhibitory recep-
tor for HLA class I molecules. Eur J Immunol. 1997;27(2):563–567.
  52.  Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence 
analysis of NKG2, a family of related cDNA clones encoding type II 
integral membrane proteins on human natural killer cells. J Exp Med. 
1991;173(4):1017–1020.
  53.  Petrie EJ, Clements CS, Lin J, et al. CD94-NKG2A recognition of 
human leukocyte antigen (HLA)-E bound to an HLA class I leader 
sequence. J Exp Med. 2008;205(3):725–735.
  54.  Le Drean E, Vely F, Olcese L, et al. Inhibition of antigen-induced   
T cell response and antibody-induced NK cell cytotoxicity by NKG2 A: 
association of NKG2 A with SHP-1 and SHP-2 protein-tyrosine 
phosphatases. Eur J Immunol. 1998;28(1):264–276.
  55.  Masilamani M, Nguyen C, Kabat J, Borrego F, Coligan J. CD94/
NKG2A inhibits NK cell activation by disrupting the actin network at 
the immunological synapse. J Immunol. 2006;177(6):3590–3596.
  56.  Carretero M, Palmieri G, Llano M, et al. Specific engagement of the 
CD94/NKG2-A killer inhibitory receptor by the HLA-E class Ib mole-
cule induces SHP-1 phosphatase recruitment to tyrosine-phosphorylated 
NKG2-A: evidence for receptor function in heterologous transfectants. 
Eur J Immunol. 1998;28(4):1280–1291.
  57.  Bauer S, Groh V , Wu J, et al. Activation of NK cells and T cells by 
NKG2D, a receptor for stress-inducible MICA. Science. 1999;285(5428): 
727–729.
  58.  Biassoni R. Natural killer cell receptors. Adv Exp Med Biol. 2008; 
640:35–52.
  59.  Sivori S, Vitale M, Morelli L, et al. p46, a novel natural killer cell-
specific surface molecule that mediates cell activation. J Exp Med. 
1997;186(7):1129–1136.
  60.  Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. 
Cytolytic granule polarization and degranulation controlled by different 
receptors in resting NK cells. J Exp Med. 2005;202(7):1001–1012.
  61.  Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor 
DAP12 bearing a tyrosine-based activation motif is involved in activat-
ing NK cells. Nature. 1998;391(6668):703–707.
  62.  Olcese L, Cambiaggi A, Semenzato G, Bottino C, Moretta A, Vivier E. 
Human killer cell activatory receptors for MHC class I molecules are 
included in a multimeric complex expressed by natural killer cells.   
J Immunol. 1997;158(11):5083–5086.
  63.  Moldovan I, Galon J, Maridonneau-Parini I, et al. Regulation of produc-
tion of soluble Fc gamma receptors type III in normal and pathological 
conditions. Immunol Lett. 1999;68(1):125–134.
  64.  Nimmerjahn F, Ravetch JV . Antibodies, Fc receptors and cancer. Curr 
Opin Immunol. 2007;19(2):239–245.
  65.  Renoux V , Bisig B, Langers I, et al. Human papillomavirus entry into 
NK cells requires CD16 expression and triggers cytotoxic activity and 
cytokine secretion. Eur J Immunol. 2011;44(11):3240–3252.
  66.  Ho EL, Heusel JW, Brown MG, Matsumoto K, Scalzo AA, 
Yokoyama WM. Murine Nkg2d and Cd94 are clustered within the 
natural killer complex and are expressed independently in natural killer 
cells. Proc Natl Acad Sci U S A. 1998;95(11):6320–6325.
  67.  Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host 
immune responses. Immunol Rev. 2010;235(1):267–285.
  68.  Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. 
A Structural basis for the association of DAP12 with mouse, but not 
human, NKG2D. J Immunol. 2004;173(4):2470–2478.
  69.  Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, 
Cosman D. UL16-binding proteins, novel MHC class I-related proteins, 
bind to NKG2D and activate multiple signaling pathways in primary 
NK cells. J Immunol. 2002;168(2):671–679.
  70.  Groh V , Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell 
stress-regulated human major histocompatibility complex class I gene 
expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A. 
1996;93(22):12445–12450.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
80
Langers et alBiologics: Targets and Therapy 2012:6
  71.  Cerwenka A. New twist on the regulation of NKG2D ligand expression. 
J Exp Med. 2009;206(2):265–268.
  72.  Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor 
involved in tumor cell lysis by activated human natural killer cells, 
is a novel member of the immunoglobulin superfamily. J Exp Med. 
1999;189(5):787–796.
  73.  Pende D, Parolini S, Pessino A, et al. Identification and molecular 
characterization of NKp30, a novel triggering receptor involved in 
natural cytotoxicity mediated by human natural killer cells. J Exp Med. 
1999;190(10):1505–1516.
  74.  Bottino C, Biassoni R, Millo R, Moretta L, Moretta A. The human natural 
cytotoxicity receptors (NCR) that induce HLA class I-  independent NK 
cell triggering. Hum Immunol. 2000;61(1):1–6.
  75.  Costello RT, Sivori S, Marcenaro E, et al. Defective expression and 
function of natural killer cell-triggering receptors in patients with acute 
myeloid leukemia. Blood. 2002;99(10):3661–3667.
  76.  Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a 
novel member of the immunoglobulin superfamily involved in trigger-
ing of natural cytotoxicity. J Exp Med. 1998;188(5):953–960.
  77.  Sivori S, Pende D, Bottino C, et al. NKp46 is the major triggering 
receptor involved in the natural cytotoxicity of fresh or cultured human 
NK cells. Correlation between surface density of NKp46 and natural 
cytotoxicity against autologous, allogeneic or xenogeneic target cells. 
Eur J Immunol. 1999;29(5):1656–1666.
  78.  Vitale M, Bottino C, Sivori S, et al. NKp44, a novel triggering surface 
molecule specifically expressed by activated natural killer cells, is 
involved in non-major histocompatibility complex-restricted tumor 
cell lysis. J Exp Med. 1998;187(12):2065–2072.
  79.  Bloushtain N, Qimron U, Bar-Ilan A, et al. Membrane-associated 
heparan sulfate proteoglycans are involved in the recognition of 
cellular targets by NKp30 and NKp46. J Immunol. 2004;173(4): 
2392–2401.
  80.  Hecht ML, Rosental B, Horlacher T, et al. Natural cytotoxicity receptors 
NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin 
sequences. J Proteome Res. 2009;8(2):712–720.
  81.  Pogge von Strandmann E, Simhadri VR, von Tresckow B, et al. Human 
leukocyte antigen-B-associated transcript 3 is released from tumor 
cells and engages the NKp30 receptor on natural killer cells. Immunity. 
2007;27(6):965–974.
  82.  Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a 
tumor cell ligand for the activating natural killer cell receptor NKp30 in 
humans. J Exp Med. 2009;206(7):1495–1503.
  83.  Stagg J, Smyth MJ. NK cell-based cancer immunotherapy. Drug News 
Perspect. 2007;20(3):155–163.
  84.  Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 
ligands of the NKG2D receptor stimulate tumour immunity. Nature. 
2001;413(6852):165–171.
  85.  Pende D, Cantoni C, Rivera P, et al. Role of NKG2D in tumor cell lysis 
mediated by human NK cells: cooperation with natural cytotoxicity 
receptors and capability of recognizing tumors of nonepithelial origin. 
Eur J Immunol. 2001;31(4):1076–1086.
  86.  Sobolev O, Stern P, Lacy-Hulbert A, Hynes RO. Natural killer cells 
require selectins for suppression of subcutaneous tumors. Cancer Res. 
2009;69(6):2531–2539.
  87.  Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y. 
NKG2D function protects the host from tumor initiation. J Exp Med. 
2005;202(5):583–588.
  88.  Street SE, Hayakawa Y, Zhan Y, et al. Innate immune surveillance of 
spontaneous B cell lymphomas by natural killer cells and gammadelta 
T cells. J Exp Med. 2004;199(6):879–884.
  89.  Zhou S, Kawakami S, Higuchi Y, Yamashita F, Hashida M. The involve-
ment of NK cell activation following intranasal administration of CpG 
DNA lipoplex in the prevention of pulmonary metastasis and peritoneal 
dissemination in mice. Clin Exp Metastasis. 2012;29(1):63–70.
  90.  Ksienzyk A, Neumann B, Nandakumar R, et al. IRF-1 expression is 
essential for natural killer cells to suppress metastasis. Cancer Res. 
2011;71(20):6410–6418.
  91.  Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural 
cytotoxic activity of peripheral-blood lymphocytes and cancer 
incidence: an 11-year follow-up study of a general population. Lancet. 
2000;356(9244):1795–1799.
  92.  Warren RP, Stembridge AM, Gardner EJ. Deficient immune function 
of peripheral blood mononuclear cells from patients with Gardner 
syndrome. Clin Exp Immunol. 1985;60(3):525–531.
  93.  Markowitz JF, Aiges HW, Cunningham-Rundles S, et al. Cancer family 
syndrome: marker studies. Gastroenterology. 1986;91(3):581–589.
  94.  Jović V , Konjević G, Radulović S, Jelić S, Spuzić I. Impaired 
perforin-dependent NK cell cytotoxicity and proliferative activity 
of peripheral blood T cells is associated with metastatic melanoma. 
Tumori. 2001;87(5):324–329.
  95.  Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y. 
Tumor growth impedes natural-killer-cell maturation in the bone 
marrow. Blood. 2006;108(1):246–252.
  96.  Reschner A, Hubert P, Delvenne P, Boniver J, Jacobs N. Innate lym-
phocyte and dendritic cell cross-talk: a key factor in the regulation of 
the immune response. Clin Exp Immunol. 2008;152(2):219–226.
  97.  Kelly JM, Darcy PK, Markby JL, et al. Induction of tumor-specific 
T cell memory by NK cell-mediated tumor rejection. Nat Immunol. 
2002;3(1):83–90.
  98.  Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated 
by MHC class I(low) targets prime dendritic cells to induce protective 
CD8 T cell responses. Immunity. 2003;19(4):561–569.
  99.  Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-
activated killer cell phenomenon. Lysis of natural killer-resistant 
fresh solid tumor cells by interleukin 2-activated autologous human 
peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823–1841.
  100.  Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant 
interleukin 2 therapy for patients with metastatic melanoma: analy-
sis of 270 patients treated between 1985 and 1993. J Clin Oncol. 
1999;17(7):2105–2116.
  101.  Sosman JA, Hank JA, Moore KH, et al. Prolonged interleukin-2 (IL-2) 
treatment can augment immune activation without enhancing antitumor 
activity in renal cell carcinoma. Cancer Invest. 1991;9(1):35–48.
  102.  Berger C, Berger M, Hackman RC, et al. Safety and immunologic 
effects of IL-15 administration in nonhuman primates. Blood. 2009; 
114(12):2417–2426.
  103.  Lauwerys BR, Garot N, Renauld JC, Houssiau FA. Cytokine pro-
duction and killer activity of NK/T-NK cells derived with IL-2, 
IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000; 
165(4):1847–1853.
  104.  Golab J, Zagozdzon R, Kozar K, et al. Potentiatied anti-tumor effec-
tiveness of combined therapy with interleukin-12 and mitoxantrone 
of L1210 leukemia in vivo. Oncol Rep. 2000;7(1):177–181.
  105.  Sondel PM, Hank JA. Antibody-directed, effector cell-mediated tumor 
destruction. Hematol Oncol Clin North Am. 2001;15(4):703–721.
  106.  Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert 
Opin Drug Saf. 2009;8(2):223–235.
  107.  Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab: a review 
of its use as adjuvant treatment in human epidermal growth factor 
receptor 2 (HER2)-positive early breast cancer. Drugs. 2010;70(2): 
215–239.
  108.  Garcia-Foncillas J, Diaz-Rubio E. Progress in metastatic colorectal 
cancer: growing role of cetuximab to optimize clinical outcome. Clin 
Transl Oncol. 2010;12(8):533–542.
  109.  Navid F, Santana VM, Barfield RC. Anti-GD2 antibody therapy for 
GD2-expressing tumors. Curr Cancer Drug Targets. 2010;10(2): 
200–209.
  110.  Bekaii-Saab TS, Roda JM, Guenterberg KD, et al. A phase I trial 
of paclitaxel and trastuzumab in combination with interleukin-12 in 
patients with HER2/neu-expressing malignancies. Mol Cancer Ther. 
2009;8(11):2983–2991.
  111.  Koh CY, Blazar BR, George T, et al. Augmentation of antitumor 
effects by NK cell inhibitory receptor blockade in vitro and in vivo. 
Blood. 2001;97(10):3132–3137.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
81
NK cells and tumor growthBiologics: Targets & Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/biologics-targets--therapy-journal
Biologics: Targets & Therapy is an international, peer-reviewed journal 
focusing on the patho-physiological rationale for and clinical applica-
tion of Biologic agents in the management of autoimmune diseases, 
cancers or other pathologies where a molecular target can be identified. 
This journal is indexed on PubMed Central, CAS, EMBase, Scopus 
and the Elsevier Bibliographic databases. The manuscript management 
system is completely online and includes a very quick and fair peer-
review system, which is all easy to use. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Biologics: Targets and Therapy 2012:6
  112.  Alici E. IPH-2101, a fully human anti-NK-cell inhibitory receptor 
mAb for the potential treatment of hematological cancers. Curr Opin 
Mol Ther. 2010;12(6):724–733.
  113.  Pegram HJ, Ritchie DS, Smyth MJ, et al. Alloreactive natural 
killer cells in hematopoietic stem cell transplantation. Leuk Res. 
2011;35(1):14–21.
  114.  Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction 
of complete and molecular remissions in acute myeloid leukemia by 
Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl 
Acad Sci U S A. 2010;107(31):13824–13829.
  115.  Viaud S, Thery C, Ploix S, et al. Dendritic cell-derived exosomes 
for cancer immunotherapy: what’s next? Cancer Res. 2010;70(4): 
1281–1285.
  116.  Hallez S, Simon P, Maudoux F, et al. Phase I/II immunogenicity of 
a Human Papillomavirus (HPV) type 16 E7 protein-based vaccine in 
women with oncogenic HPV-positive cervical intraepithelial neoplasia. 
Cancer Immunol Immunother. 2004;53(7):642–650.
  117.  Hubert P, Doyen J, Capelle X, et al. Local applications of GM-CSF 
induce the recruitment of immune cells in cervical low-grade squamous 
intraepithelial lesions. Am J Reprod Immunol. 2010;64:126–136.
  118.  Andresen L, Skovbakke S, Persson G, et al. 2-Deoxy d-glucose 
  prevents cell surface expression of nkg2d ligands through inhibition 
of n-linked glycosylation. J Immunol. 2012;188(4):1847–1855.
  119.  Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage path-
way regulates innate immune system ligands of the NKG2D receptor. 
Nature. 2005;436(7054):1186–1190.
  120.  Lunemann A, Lunemann JD, Munz C. Regulatory NK-cell 
functions in inflammation and autoimmunity. Mol Med. 
2009;15(9–10):352–358.
  121.  Shi FD, Ljunggren HG, Sarvetnick N. Innate immunity and autoim-
munity: from self-protection to self-destruction. Trends Immunol. 
2001;22(2):97–101.
  122.  Shah AA, Rosen A. Cancer and systemic sclerosis: novel insights 
into pathogenesis and clinical implications. Curr Opin Rheumatol. 
2011;23(6):530–535.
  123.  Amos SM, Duong CP, Westwood JA, et al. Autoimmunity associated 
with immunotherapy of cancer. Blood. 2011;118(3):499–509.
  124.  Shi FD, Zhou Q. Natural killer cells as indispensable players and thera-
peutic targets in autoimmunity. Autoimmunity. 2011;44(1):3–10.
  125.  Shi FD, Wang HB, Li H, et al. Natural killer cells determine 
the outcome of B cell-mediated autoimmunity. Nat Immunol. 
2000;1(3):245–251.
  126.  Kitaichi N, Kotake S, Morohashi T, Onoe K, Ohno S, Taylor AW. 
Diminution of experimental autoimmune uveoretinitis (EAU) in mice 
depleted of NK cells. J Leukoc Biol. 2002;72(6):1117–1121.
  127.  Erkeller-Yusel F, Hulstaart F, Hannet I, Isenberg D, Lydyard P. 
Lymphocyte subsets in a large cohort of patients with systemic lupus 
erythematosus. Lupus. 1993;2(4):227–231.
  128.  Aramaki T, Ida H, Izumi Y, et al. A significantly impaired natural killer 
cell activity due to a low activity on a per-cell basis in rheumatoid 
arthritis. Mod Rheumatol. 2009;19(3):245–252.
  129.  Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory 
CD56(bright) natural killer cells mediate immunomodulatory effects 
of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. 
Proc Natl Acad Sci U S A. 2006;103(15):5941–5946.
  130.  Li Z, Lim WK, Mahesh SP, Liu B, Nussenblatt RB. Cutting edge: 
in vivo blockade of human IL-2 receptor induces expansion of 
CD56(bright) regulatory NK cells in patients with active uveitis.   
J Immunol. 2005;174(9):5187–5191.
  131.  Ogasawara K, Hamerman JA, Hsin H, et al. Impairment of NK 
cell function by NKG2D modulation in NOD mice. Immunity. 
2003;18(1):41–51.
  132.  Namekawa T, Snyder MR, Yen JH, et al. Killer cell activating 
receptors function as costimulatory molecules on CD4+CD28null 
T cells clonally expanded in rheumatoid arthritis. J Immunol. 
2000;165(2):1138–1145.
  133.  Martin MP, Nelson G, Lee JH, et al. Cutting edge: susceptibility 
to psoriatic arthritis: influence of activating killer Ig-like recep-
tor genes in the absence of specific HLA-C alleles. J Immunol. 
2002;169(6):2818–2822.
  134.  Momot T, Koch S, Hunzelmann N, et al. Association of killer cell 
immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 
2004;50(5):1561–1565.
  135.  Suzuki Y, Hamamoto Y, Ogasawara Y, et al. Genetic polymor-
phisms of killer cell immunoglobulin-like receptors are associ-
ated with susceptibility to psoriasis vulgaris. J Invest Dermatol. 
2004;122(5):1133–1136.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
82
Langers et al